公开(公告)号：US20120232039A1

公开(公告)日：2012-09-13

申请号：US13412032

申请日：2012-03-05

申请人： Amjad ALI ,  Michael Man-Chu Lo ,  Brent Whitehead ,  Shrenik K. Shah ,  Lin Yan ,  Timothy J. Henderson ,  Zack Zhiqiang Guo

发明人： Amjad ALI ,  Michael Man-Chu Lo ,  Brent Whitehead ,  Shrenik K. Shah ,  Lin Yan ,  Timothy J. Henderson ,  Zack Zhiqiang Guo

IPC分类号： A61K31/655 ,  A61P9/12 ,  C07C245/24

CPC分类号： C07D211/46 ,  C07D207/12 ,  C07D207/273 ,  C07D207/48 ,  C07D211/96 ,  C07D223/08 ,  C07D309/12 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/12

摘要： A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

摘要翻译： 具有用于治疗高血压，肺动脉高压（PAH），充血性心力衰竭，由过度保水引起的病症，心血管疾病，糖尿病，氧化应激，内皮功能障碍，肝硬化，先兆子痫，骨质疏松症或肾病的结构的化合物。

公开(公告)号：US10357481B2

公开(公告)日：2019-07-23

申请号：US15579878

申请日：2016-06-27

申请人： MERCK SHARP & DOHME CORP. ,  Gregori J. Morriello ,  Lehua Chang ,  Ashley Forster ,  Yili Chen ,  Michael P. Dwyer ,  Zack Zhiqiang Guo ,  Ming Wang ,  Shimin Xu ,  Yingjian Bo ,  Jianmin Fu

发明人： Gregori J. Morriello ,  Lehua Chang ,  Ashley Forster ,  Yili Chen ,  Michael P. Dwyer ,  Zack Zhiqiang Guo ,  Ming Wang ,  Shimin Xu ,  Yingjian Bo ,  Jianmin Fu

IPC分类号： A61K31/4196 ,  C07D471/04 ,  C07D487/04 ,  A61P25/28 ,  A61P25/22 ,  A61P25/18 ,  A61P25/16 ,  A61P25/06 ,  A61K31/52

摘要： The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

公开(公告)号：US20180169072A1

公开(公告)日：2018-06-21

申请号：US15579878

申请日：2016-06-27

申请人： Gregori J. MORRIELLO ,  Lehua CHANG ,  Ashley FORSTER ,  Yili CHEN ,  Michael P. DWYER ,  Zack Zhiqiang GUO ,  Ming WANG ,  Shimin XU ,  Yingjian BO ,  Jianmin FU ,  MERCK SHARP & DOHME CORP.

发明人： Gregori J. MORRIELLO ,  Lehua CHANG ,  Ashley FORSTER ,  Yili CHEN ,  Michael P. DWYER ,  Zack Zhiqiang GUO ,  Ming WANG ,  Shimin XU ,  Yingjian BO ,  Jianmin FU

IPC分类号： A61K31/4196 ,  A61K31/52 ,  A61P25/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

CPC分类号： A61K31/4196 ,  A61K31/52 ,  A61P25/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28 ,  C07D471/04 ,  C07D487/04

摘要： The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.